These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Reduced circulating microRNA-203 predicts poor prognosis for glioblastoma.
    Author: Chen J, Yang L, Wang X.
    Journal: Cancer Biomark; 2017 Dec 06; 20(4):521-526. PubMed ID: 28946553.
    Abstract:
    BACKGROUND: MicroRNAs (miRNAs) have been demonstrated to play an important role in the development and progression of various types of cancer including glioblastoma (GBM). OBJECTIVE: The aim of this study was to investigate the expression pattern and prognostic significance of serum miR-203 in patients with GBM. METHODS: miR-203 extracted from cell culture medium and serum samples was detected by real-time PCR. The correlation between serum miR-203 expression as well as clinicopathological characteristics and patient survival was determined. RESULTS: The expression level of miR-203 was remarkably reduced in the GBM cells and their culture medium. Serum miR-203 expression was significantly decreased in GBM patients compared with low grade glioma (LGG) patients and healthy controls. In addition, serum miR-203 discriminated GBM patients from LGG patients and healthy subjects. Chi-squared analysis showed that a significant correlation was found between low serum miR-203 expression and larger tumor size as well as lower Karnofsky Performance Scale scores. Patients with lower serum miR-203 suffered poorer overall survival (OS) and progression free survival (PFS). Multivariate analysis indicated that low miR-203 expression is an independent prognostic factor for poor OS in GBM patients. CONCLUSIONS: These data demonstrate that serum miR-203 expression might serve as a potential prognostic indicator of GBM.
    [Abstract] [Full Text] [Related] [New Search]